Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT03182400
Recruiting Not applicable

Neurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults

NCT03182400 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Tours
Phase
Not applicable
Started
2017-06-14
Last updated
2022-09-09

Condition(s) studied

Healthy Volunteer

Investigational drug(s) / intervention(s)

Neurophysiological assessmentNeuropsychological assessment

Neurophysiological assessment: Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments

Neuropsychological assessment: sub-tests, scales, surveys, reaction time measurement

Study summary

It is now widely accepted that autism is linked to a developmental disorder and cerebral function.

Our research team (UMR U930 INSERM, François-Rabelais University of Tours, whom Pr F Bonnet-Brilhault is responsible for team "Autism") hypothesizes that atypical sensory information processing, especially auditory and / or visual information, could underly the symptoms observed in autism. A better knowledge of the typical development of the sensory and cognitive processes must therefore make it possible in the long term to identify the abnormalities linked to the autism spectrum disorders (ASD).

Studies in healthy subjects are therefore necessary in order to identify neurophysiological indices of cerebral functioning and to study their evolution during normal development, making it possible in the future to compare with populations of subjects with ASD.

The investigators intend to study the development of all the cognitive processes involved in the processing of sensory and, in particular, auditory and visual information in humans: from low-level perception processes to higher-level cognitive processes (attention, emotion, language, prediction, ...). For this the investigators will use non-invasive neurophysiological explorations (EEG, eye tracking) as well as neuropsychological explorations (Questionnaires or spontaneous language recording).

A better understanding of the pathophysiological mechanisms underlying the symptoms observed in autism could ultimately lead to the development of new specific therapeutic strategies, particularly in the field of exchange and development therapy or cognitive remediation .

Eligibility

Sex
ALL
Min age
1 Year
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Between 1 and 60 years-old * Able to understand and apply instructions for a task * Information of subject or legal representant * Informed written consent of subject or legal representant * Affiliation to the social security system Exclusion Criteria: * Abnormal corrected vision * Abnormal audition * Known personal neurological pathology * Known personal psychiatric problems * Identified difficulties for walking, language, or learning * Exclusion period because of participation to another experimental protocol * Adult with legal protection

Primary outcome measure(s)

  • ERP amplitude (µV) — 1 hour
    analysis of ERP amplitude evoked during EEG recording

Trial sites (1)

FacilityCityRegionStatus
Chru Tours Tours France Recruiting

More University Hospital, Tours trials in France

Transcranial Ultrasound Assessment of Cerebral Pulsatility in Shunt Decision-making for Suspected Idiopathic Normal Pressure Hydrocephalus: a Prospective Cohort Study Starting soon
Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients Recruiting
Feasibility and Efficacy of Cognitive-Behavioral Therapy for Patients With ADHD/Behavioral Addiction Comorbidity Recruiting
Acetylsalicylic Acid Versus Placebo as an add-on Treatment to Local Non-steroidal Anti-inflammatory Drug for the Management of Thrombotic Episodes in Superficial Venous Malformations in Children Aged 6 to 17 Years. Starting soon
Collection of Primary Human Recruiting

Other trials for the same condition

Neural Mechanisms of Emotion-behaviour Interactions Starting soon
Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease Recruiting
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec Active, not recruiting
Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery Recruiting
Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03182400 on ClinicalTrials.gov ↗ ← All trials in France